Tenet Healthcare Corporation (THC) Stock: Price, Forecast & Analyst Target
Tenet Healthcare Corporation (THC) — MoonshotScore 89/100 (Exceptional band), calculated Oct 5, 2026. Price $263.73 (+1.98%), as of the Oct 5, 2026 trading session; market cap $21.2B. Expected results Oct 29, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 9.77× (market value Oct 5, 2026; cash Jun 30, 2026) · expected results Oct 29, 2026
Tenet Healthcare Corporation · THC · NYSE · Healthcare · Medical - Care Facilities
Research dated 2026-09-12: Tenet Healthcare earns from acute hospital care, ambulatory procedures and Conifer’s administrative services for healthcare organizations. Its durability depends on whether operational gains and greater capital deployment into USPI can sustain cash generation while debt remains far larger than liquid resources.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Tenet Healthcare (THC)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, at a cheap price, but a strained balance sheet; the market is already moving on it. Business Quality: Elite; Financial Safety: Strained; Valuation: Cheap; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $5.63B (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 8 of 8
- Altman Z 2.09 · Piotroski F 7
Helping: business quality, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 89 | Exceptional | |
| 89 | Exceptional | |
| 89 | Exceptional | |
| 89 | Exceptional | |
| 90 | Exceptional | |
| 90 | Exceptional |
The score was 89 in the stored Oct 4, 2026 snapshot and remains 89 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $263.73 | |
| Change on the day | +1.98% | |
| 52-week range | $157.58 – $283.05 | |
| Market capitalisation | $21.2B | |
| Price / earnings (trailing) | 9.90 | |
| Shares traded on the day | 148.2K | |
| Beta (volatility vs the S&P 500) | 1.23 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
This increase is driven by fundamental improvements in our operations that benefited our results in the first half of the year and that we expect to continue into the back half of the year.
Sun Park · Statement from
Finally, we expect third quarter '26 consolidated adjusted EBITDA and to be in the range of 23% to 24% of our full year consolidated adjusted EBITDA at the midpoint, and we expect third quarter '26 USPI EBITDA to be in the range of 24% to 25% of our full year USPI adjusted EBITDA at the midpoint. Turning to our cash flows for '26, we now expect adjusted free cash flow after NCI in the range of $1.825 billion to $2.055 billion, an increase of $225 million at the midpoint from our previous guidance range.
Sun Park · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Tenet Healthcare (THC): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the THC film — every key number, told as a short cinematic story
~2 min · open the film
What is Tenet Healthcare (THC), and what does it report?
Short answer · as of
Tenet Healthcare Corporation operates as a broad-ranging provider of health solutions. The company organizes its operations across three main divisions: Hospital Operations and Other, Ambulatory Care, and Conifer.
Research dated 2026-09-12.
Tenet is more than a hospital operator. Hospitals deliver acute and highly specialized care, ambulatory facilities handle procedures and related services outside the traditional hospital setting, and Conifer manages revenue cycles, patient communications and care-focused administrative workflows for healthcare clients.
The consolidated accounts therefore combine care delivery with contracted business-process services. Ambulatory Care and Hospital Operations sit at nearly the same reported scale, making the mix between settings as important as the consolidated revenue line.
What do the latest results show for Tenet Healthcare (THC)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $5.63B.
Research dated 2026-09-12.
Revenue recovered from the prior dip and moved beyond its earlier high in the displayed quarterly series. Net result and diluted earnings also reached displayed peaks, while operating result improved without surpassing an older high; this quarterly acceleration follows an annual period when revenue advanced but net result retreated.
The latest reported result cleared revenue and earnings estimates. Earnings have repeatedly surpassed estimates across the displayed history, although revenue has been less consistent against expectations.
Management attributes the stronger outlook to fundamental operating improvements and expects those benefits to continue. It also expects exchange erosion and broader market conditions to persist, so that explanation should be treated as a claim to test against subsequent results rather than as a completed transformation.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $5.63B Jun 30, 2026
- Latest quarter · SG&A
- $2.23B Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $1.02B Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $5.63B | Not available | $2.23B | $1.02B |
| Mar 31, 2026 | $5.37B | Not available | $2.17B | $882.00M |
| Dec 31, 2025 | $5.53B | Not available | $0.00 | $869.00M |
| Sep 30, 2025 | $5.29B | Not available | $2.20B | $889.00M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $5.63B Jul 23, 2026
- Latest report · revenue estimate
- $5.43B Jul 23, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 23, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 23, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 23, 2026 | $5.63B | $5.43B | $6.1200 | $4.2600 |
| Apr 30, 2026 | $5.37B | $5.39B | $4.8200 | $4.1700 |
| Feb 11, 2026 | $5.53B | $5.47B | $4.7000 | $4.0700 |
| Oct 28, 2025 | $5.29B | $5.26B | $3.7000 | $3.3400 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $5.63B | $826M | $9.84 (diluted) |
| Q1 FY2026 | $5.37B | $702M | $8.01 (diluted) |
| Q4 FY2025 | $5.53B | $371M | $4.22 (diluted) |
| Q3 FY2025 | $5.29B | $342M | $3.86 (diluted) |
What are the financial strengths and risks for Tenet Healthcare (THC)?
Short answer
Cash and short-term investments were $2.17B at the Jun 30, 2026 balance-sheet date. Operating cash flow was $585.00M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Tenet generates substantial operating cash, and recent operating inflows have exceeded capital spending. Cash conversion is not steady, however: the latest inflow fell sharply from the preceding period, and the cash balance has declined materially across the displayed window.
Reported liquidity ratios indicate coverage of current obligations, but total debt greatly exceeds cash and short-term investments. That leverage raises the importance of dependable cash conversion as Tenet directs more capital toward USPI.
Persistent exchange erosion is the clearest identified operating pressure. If operational gains fail to offset it while capital deployment continues, weaker cash conversion would leave less flexibility against the debt burden.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $585.00M Jun 30, 2026
- Previous quarter · operating cash flow
- $1.64B Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $585.00M | −$168.00M |
| Mar 31, 2026 | $1.64B | −$180.00M |
| Dec 31, 2025 | $731.00M | −$364.00M |
| Sep 30, 2025 | $1.06B | −$280.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Tenet Healthcare (THC)?
Short answer · as of
The next earnings report is expected on Oct 29, 2026.
Research dated 2026-09-12.
At the scheduled earnings release, watch whether revenue remains near its recent high, operating profit continues to advance and earnings maintain their record of exceeding expectations. The consensus path assumes gradual revenue expansion but an uneven earnings progression, making operating performance more informative than a smooth headline growth story.
Cash deserves equal attention. A recovery in operating cash flow, stabilization of the cash balance and evidence that USPI spending is producing durable operating gains would support management’s outlook; continued cash depletion alongside heavy debt would weaken it.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
This increase is driven by fundamental improvements in our operations that benefited our results in the first half of the year and that we expect to continue into the back half of the year.
Sun Park ·
Finally, we expect third quarter '26 consolidated adjusted EBITDA and to be in the range of 23% to 24% of our full year consolidated adjusted EBITDA at the midpoint, and we expect third quarter '26 USPI EBITDA to be in the range of 24% to 25% of our full year USPI adjusted EBITDA at the midpoint. Turning to our cash flows for '26, we now expect adjusted free cash flow after NCI in the range of $1.825 billion to $2.055 billion, an increase of $225 million at the midpoint from our previous guidance range.
Sun Park ·
So I would say both of these metrics were roughly in line with our expectations, both for the quarter as we exited Q1 into Q2, we expected after the grace periods for exchange erosion to increase, obviously, from Q1 to Q2, and then we expect the overall market trends that we saw in Q2 to roughly continue into Q3 and Q4 rest of the year, which is why we didn't change our guidance. .
Sun Park ·
And then obviously, the deployment and increase in our guidance for deployment of capital into the USPI segment this year.
Saumya Sutaria ·
How does Tenet Healthcare compare with its peers?
Short answer
Tenet Healthcare's score ranks 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Tenet combines acute-care hospitals, ambulatory procedure sites and Conifer’s healthcare administration services. Compared with a hospital-focused operator, its procedure-site demand and administrative contract activity can diverge from conditions inside acute-care facilities.
Ambulatory Care and Hospital Operations are reported at nearly comparable scale, while Conifer adds a different revenue mechanism. That operating breadth is paired with substantial leverage, so comparisons based only on consolidated sales miss the importance of business mix and cash conversion.
| Company | Price | Market value | Score |
|---|---|---|---|
| $230.37 Oct 5, 2026 | $3.60B | 98 5-pillar Oct 5, 2026 | |
| $176.05 Oct 5, 2026 | $10.7B | 94 5-pillar Oct 5, 2026 | |
| $12.22 Oct 5, 2026 | $4.74B | 93 5-pillar Oct 5, 2026 | |
| $120.97 Oct 5, 2026 | $12.0B | 90 5-pillar Oct 5, 2026 | |
| Tenet Healthcare (THC) — this page | $263.73 | $21.2B | 89 |
| $511.30 Oct 5, 2026 | $6.63B | 87 5-pillar Oct 5, 2026 | |
| $22.65 Oct 5, 2026 | $12.0B | 83 5-pillar Oct 5, 2026 | |
| $434.92 Oct 5, 2026 | $92.4B | 82 5-pillar Oct 5, 2026 | |
| $23.37 Oct 5, 2026 | $3.50B | 81 5-pillar Oct 5, 2026 | |
| $12.37 Oct 5, 2026 | $2.68B | 81 5-pillar Oct 5, 2026 | |
| $172.89 Oct 5, 2026 | $10.1B | 75 5-pillar Oct 5, 2026 | |
| $178.72 Oct 5, 2026 | $11.5B | 75 5-pillar Oct 5, 2026 | |
| $88.03 Oct 5, 2026 | $15.2B | 61 5-pillar Oct 5, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $242.00 – $308.00
- Consensus target
- $283.36
- Median target
- $284.00
Consensus record · Captured .
Measured against a quoted price of $263.73 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Sep 14, 2026
- Transactions
- 60
- Identified insiders
- 14
- Purchases
- 0
- Sales
- 25
- Other transactions
- 35
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 93.1% Period end Jun 30, 2026
- Previous quarter · ownership
- 94.5% Prior to period end Jun 30, 2026
- Reporting holders
- 717 Period end Jun 30, 2026
- Previous quarter · holders
- 735 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 8,743,005 |
| Price T Rowe Associates INC /Md/ | 7,957,449 |
| Boston Partners | 4,433,360 |
| Vanguard Portfolio Management LLC | 4,238,108 |
| Fmr LLC | 3,994,545 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Tenet Healthcare (THC)?
What Investors Ask About Tenet Healthcare (THC) — Healthcare
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Tenet’s Conifer business sell?
Conifer provides revenue-cycle administration, patient communication and engagement support, and care-focused business processes to hospitals, health systems, physician practices, employers and other clients.
Why is USPI important to Tenet’s capital plan?
Management increased planned capital deployment into USPI while also raising its cash-flow outlook. The key test is whether that spending produces sustained operating improvement without adding pressure to a declining cash balance.
How do Tenet’s ambulatory centers change its hospital exposure?
Ambulatory facilities let Tenet earn from surgical and diagnostic activity outside traditional acute-care hospitals. Their reported scale is close to Hospital Operations, so Tenet’s economics cannot be read solely through hospital conditions.
What must improve for Tenet’s cash balance to stabilize?
Operating inflows need to remain comfortably above capital spending and other cash uses. Recent cash flow has covered capital expenditure, but the liquid balance has still fallen substantially while debt remains much larger.
What is the THC stock price today?
The last price recorded on this page for Tenet Healthcare Corporation (THC) is $263.73, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the THC price target?
The analyst consensus price target for Tenet Healthcare Corporation (THC) is $283.36 (range $242.00 to $308.00, median $284.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (80 figures)
The 80 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Sun Park (Jul 24, 2026): This increase is driven by fundamental improvements in our operations that benefited our results in the first half of the year and that we expect to continue into the back half of the year. Sun Park (Jul 24, 2026): Finally, we expect third quarter '26 consolidated adjusted EBITDA and to be in the range of 23% to 24% of our full year consolidated adjusted EBITDA at the midpoint, and we expect third quarter '26 USPI EBITDA to be in the range of 24% to 25% of our full year USPI adjusted EBITDA at the midpoint. Turning to our cash flows for '26, we now expect adjusted free cash flow after NCI in the range of $1.825 billion to $2.055 billion, an increase of $225 million at the midpoint from our previous guidance range. Sun Park (Jul 24, 2026): So I would say both of these metrics were roughly in line with our expectations, both for the quarter as we exited Q1 into Q2, we expected after the grace periods for exchange erosion to increase, obviously, from Q1 to Q2, and then we expect the overall market trends that we saw in Q2 to roughly continue into Q3 and Q4 rest of the year, which is why we didn't change our guidance. . Saumya Sutaria (Jul 24, 2026): And then obviously, the deployment and increase in our guidance for deployment of capital into the USPI segment this year. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Dallas, TX | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "14201 Dallas Parkway, Dallas, TX, 75254, US". |
FMP — 70 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 29, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $263.73 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T17:14:51.508Z. | |
px.change | Change on the day | +1.98% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $21.2B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T17:13:59.000Z. Captured from FMP at 2026-10-05T17:14:49.828Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$5.11 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $5.63B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 9.90 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 148.2K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 1.23 | FMP | Financial Modeling Prep (FMP) company profile | |
id.business_summary | Business description (FMP excerpt) | Tenet Healthcare Corporation operates as a broad-ranging provider of health solutions. The company organizes its operations across three main divisions: Hospital Operations and Other, Ambulatory Care, and Conifer. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
id.ceo | Chief executive | Saumya Sutaria | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 88,500 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $19.48B, net result $914.00M; FY2022 revenue $19.17B, net result $411.00M; FY2023 revenue $20.55B, net result $611.00M; FY2024 revenue $20.66B, net result $3.20B; FY2025 revenue $21.31B, net result $1.41B | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Ambulatory Care $5.17B · Hospital Operations $5.13B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 26.9% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $5.63B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $2.23B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $1.02B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $5.37B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $2.17B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $882.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $5.53B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $869.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $5.29B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $2.20B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $889.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-07-23.revenue_actual | Revenue · reported — report date 2026-07-23 | $5.63B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-23.revenue_estimated | Revenue · estimate — report date 2026-07-23 | $5.43B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-23.eps_actual | EPS · reported — report date 2026-07-23 | $6.1200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-23.eps_estimated | EPS · estimate — report date 2026-07-23 | $4.2600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.revenue_actual | Revenue · reported — report date 2026-04-30 | $5.37B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.revenue_estimated | Revenue · estimate — report date 2026-04-30 | $5.39B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.eps_actual | EPS · reported — report date 2026-04-30 | $4.8200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.eps_estimated | EPS · estimate — report date 2026-04-30 | $4.1700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-11.revenue_actual | Revenue · reported — report date 2026-02-11 | $5.53B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-11.revenue_estimated | Revenue · estimate — report date 2026-02-11 | $5.47B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-11.eps_actual | EPS · reported — report date 2026-02-11 | $4.7000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-11.eps_estimated | EPS · estimate — report date 2026-02-11 | $4.0700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.revenue_actual | Revenue · reported — report date 2025-10-28 | $5.29B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.revenue_estimated | Revenue · estimate — report date 2025-10-28 | $5.26B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.eps_actual | EPS · reported — report date 2025-10-28 | $3.7000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.eps_estimated | EPS · estimate — report date 2025-10-28 | $3.3400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $2.17B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $585.00M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $13.25B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 4.64× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $585.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $1.64B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$168.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$180.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $731.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$364.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $1.06B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$280.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $242.00 – $308.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $283.36 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $284.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 60 transactions · 0 purchases, 25 sales, 35 other transactions · 14 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Sep 14, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 93.1% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 94.5% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 717 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 735 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 8,743,005 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Price T Rowe Associates INC /Md/ — shares in provider snapshot | 7,957,449 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Boston Partners — shares in provider snapshot | 4,433,360 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 4,238,108 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Fmr LLC — shares in provider snapshot | 3,994,545 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 8 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-04 | |
fin.scores | Distress and quality screens | Altman Z 2.09 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
px.range52 | 52-week range | $157.58 – $283.05 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 9.77× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $2.17B at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-07-23.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($5.63B) with the recorded estimate ($5.43B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-23.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($6.1200) with the recorded estimate ($4.2600) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 89 of 100 · Exceptional · pillars 87 / 37 / 85 / 85 / 87 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 89 (stored snapshot Oct 4, 2026) → 89 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-07-23. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-23.revenue_actual,earn.history.depth.2026-07-23.revenue_estimated,earn.history.depth.2026-07-23.revenue_actual.comparison,earn.history.depth.2026-07-23.eps_actual.comparison,earn.history.depth.2026-07-23.eps_actual,earn.history.depth.2026-07-23.eps_estimated,earn.history.depth.2026-04-30.revenue_actual,earn.history.depth.2026-04-30.revenue_estimated,earn.history.depth.2026-04-30.eps_actual,earn.history.depth.2026-04-30.eps_estimated,earn.history.depth.2026-02-11.revenue_actual,earn.history.depth.2026-02-11.revenue_estimated,earn.history.depth.2026-02-11.eps_actual,earn.history.depth.2026-02-11.eps_estimated,earn.history.depth.2025-10-28.revenue_actual,earn.history.depth.2025-10-28.revenue_estimated,earn.history.depth.2025-10-28.eps_actual,earn.history.depth.2025-10-28.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Tenet Healthcare Corporation operates as a broad-ranging provider of health solutions. The company organizes its operations across three main divisions: Hospital Operations and Other, Ambulatory Care, and Conifer. Within its network of acute care facilities, Tenet delivers a full spectrum of essential services. These include core hospital functions such as operating and recovery suites, radiology and respiratory therapy, clinical laboratories, and on-site pharmacies. The organization also provides high-acuity patient care through intensive, critical, and coronary care units. Specialized medical services cover areas like cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics, alongside various outpatient treatments, including physical therapy. Advanced surgical capabilities feature cardiothoracic, complex spinal, and neurosurgery, as well as neonatal intensive care. Tenet extends its offerings to ultra-specialized quaternary care, exemplified by heart and kidney transplant programs, and sophisticated procedures such as limb-salvaging vascular interventions, acute Level 1 trauma care, intravascular stroke treatment, minimally invasive cardiac valve replacements, advanced imaging, and telemedicine access. Beyond its hospital network, Tenet manages numerous other clinical sites. These encompass outpatient surgical centers, immediate care facilities, diagnostic imaging centers, dedicated surgical hospitals, off-campus emergency departments, and micro-hospitals. Through its Conifer segment, the company furnishes critical healthcare business process solutions. These administrative services, offered to hospitals, health systems, physician practices, employers, and other clients, include financial administration for patient accounts (revenue cycle management), support for patient communications and engagement, and outcome-focused care strategies. As of February 9, 2022, Tenet's operational footprint included 60 hospitals and roughly 550 additional medical facilities. This count of additional sites comprises surgical hospitals, ambulatory surgery centers, urgent care and imaging centers, and various other clinical locations. Tenet Healthcare Corporation was established in 1975 and maintains its principal office in Dallas, Texas. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Ambulatory Care: $5.17B; Hospital Operations: $5.13B | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-07-24 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Cash, investments and debt | Total debt: $13.25B; Liquidity basis: cash and short-term investments; Total liabilities: $21.98B; Cash and short-term investments: $2.17B; Cash and investments: $2.17B; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-23 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $2.17B; Cash and short-term investments: $2.17B; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $2.17B; Decline: $1.92B; Opening balance: $4.09B; Average change per period: $274.90M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$11.08B; Total debt: $13.25B; Cash and investments: $2.17B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 1.35; Current ratio: 1.41; Debt to equity: 2.84; Net margin: 10.3%; Gross margin: 26.9%; Operating margin: 16.8%; Return on assets: 7.3%; Return on equity: 50.6% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Next earnings report | Date: 2026-10-27; EPS estimate: $4.67 per share; Revenue estimate: $5.49B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.
ETFs that hold THC
Funds in our ETF coverage that list THC among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Concourse Capital Focused Equity ETF (CCFE) | 4.93% | |
| Texas Capital Texas Equity Index ETF (TXS) | 4.75% | |
| IHF ETF | 3.55% | |
| XHS ETF | 2.40% |